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assessment of the scientific elements put forward by Hungary to support 
the prohibition for the placing on the market of GM potato EH92-527-1 for 
cultivation purposes in Hungary
1
 
EFSA Panel on Genetically Modified Organisms (GMO)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Hungary notified to the European Commission its scientific arguments justifying the implementation of a 
national safeguard measure prohibiting the placing on the market of GM potato EH92-527-1 for cultivation 
purposes in Hungary, after which the European Commission asked the European Food Safety Authority (EFSA) 
to assess the scientific information supporting the prohibition. Having considered the information package 
provided by Hungary and all relevant scientific publications, the EFSA Panel on Genetically Modified 
Organisms (GMO Panel) concluded that (i) no new data specific to the safety of the nptII gene have been 
provided; (ii) the therapeutic relevance of kanamycin and neomycin was already addressed in the previous 
EFSA opinion on antibiotic resistance marker genes and kanamycin resistance in Mycobacterium tuberculosis 
results largely from chromosomal mutations and not from the transfer of aminoglycoside resistance genes such 
as nptII; (iii) the knowledge gaps and uncertainties highlighted in the Hungarian document have already been 
considered in the previous EFSA opinion on antibiotic resistance marker genes, and no new information on the 
safety of nptII gene as present in the GM potato EH92-527-1 has been identified in the scientific literature that 
would cause the GMO Panel to change its previous conclusions. Therefore, the EFSA GMO Panel concludes 
that no grounds exist to date that would lead to reconsideration of its opinion on GM potato EH92-527-1. 
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SUMMARY 
Following a request from the European Commission, the Panel on Genetically Modified Organisms 
(GMO) was asked to deliver a scientific opinion on the elements put forward by Hungary to support 
the prohibition for the placing on the market of GM potato EH92-527-1 for cultivation purposes in 
Hungary. 
In December 2010, Hungary notified to the EC its scientific argumentation justifying the 
implementation of a national safeguard measure prohibiting the placing on the market of GM potato 
EH92-527-1 for cultivation purposes in Hungary, according to Article 23 of Directive 2001/18/EC on 
the deliberate release in the environment of genetically modified organisms. 
On 23 May 2012, the European Food Safety Authority (EFSA) was requested by the European 
Commission to assess the scientific information submitted by the Hungarian Authorities in the context 
of a safeguard clause invoked under Article 23 of Directive 2001/18/EC. 
In light of the information package provided by Hungary in support of its safeguard clause and, 
having considered all relevant scientific publications, the GMO Panel concludes that: 
Hungary did not provide any new or additional information made available since the date of consent 
for this GM event that would affect the environmental risk assessment or the reassessment of existing 
information on the basis of new or additional scientific knowledge. New data specific to the safety of 
the nptII gene have not been provided. 
The therapeutic relevance of kanamycin and neomycin was already addressed in the previous EFSA 
opinion on antibiotic resistance marker genes. Kanamycin resistance in Mycobacterium tuberculosis 
results largely from chromosomal mutations and not from the transfer of aminoglycoside resistance 
genes such as nptII. 
The knowledge gaps and uncertainties highlighted in the Hungarian document have already been 
considered in the previous EFSA opinion on antibiotic resistance marker genes. EFSA continually 
reviews the scientific literature. No new information on the safety of the nptII gene, as present in the 
GM potato EH92-527-1, was identified in the scientific literature that would cause the GMO Panel to 
change its earlier conclusions. 
The EFSA GMO Panel concludes that no detailed grounds exist to date that would lead to 
reconsideration of its opinion on GM potato EH92-527-1. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
In February 2006, the European Food Safety Authority (EFSA) adopted an opinion related to the 
placing on the market of GM potato EH92-527-1 for cultivation and industrial starch production, 
following a notification submitted by BASF Plant Science to the Swedish Authorities. 
On 11 June 2009, EFSA published a joint scientific opinion of the Panel on Genetically Modified 
Organisms (GMO) and the Panel on Biological Hazards (BIOHAZ) on the “Use of antibiotic 
resistance genes as marker genes in genetically modified plants” and a scientific opinion of the GMO 
Panel on “Consequences of the opinion on the use of antibiotic resistance genes as marker genes in 
genetically modified plants on previous EFSA assessments of individual GM plants”. 
On 2 March 2010, the European Commission (EC) adopted a decision authorising the placing on the 
market of GM potato EH92-527-1 for cultivation and industrial starch production. 
In December 2010, Hungary notified to the EC its scientific argumentation justifying the 
implementation of a national safeguard measure prohibiting the placing on the market of GM potato 
EH92-527-1 for cultivation purposes in Hungary, according to Article 23 of Directive 2001/18/EC on 
the deliberate release in the environment of genetically modified organisms. 
In order for the EC to follow-up on this safeguard clause in accordance with Article 23 of Directive 
2001/18/EC, it was deemed appropriate by EC that EFSA would assess the scientific elements 
provided by Hungary. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
EFSA was requested in accordance with Article 29 of Regulation (EC) No 178/2002 to assess the 
scientific information submitted by the Hungarian Authorities justifying their national safeguard 
measure concerning GM potato EH92-527-1 and to identify whether these new scientific elements 
might lead the GMO Panel to reconsider its opinion on GM potato EH92-527-1 from 2006. 
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ASSESSMENT 
1. Introduction 
Directive 2001/18/EC provides the possibility for the Member States to invoke safeguard measures on 
specific genetically modified organisms in the case where new or additional information, made 
available since the date of the consent, or reassessment of existing information on the basis of new or 
additional scientific knowledge would affect the risk assessment of an authorised GMO. Provisions 
foreseen by Hungary seek to provisionally prohibit the marketing of potato EH92-527-1 for cultivation 
purposes in Hungary. 
The EFSA GMO Panel examined the set of supporting documents submitted by Hungary. In this 
respect, the GMO Panel assessed whether the submitted documents comprise new scientific 
information that would change the outcome of previously performed risk assessments, and if detailed 
grounds exist that would lead the GMO Panel to reconsider its opinion on GM potato EH92-527-1 
(EFSA, 2006). 
The GMO Panel looked for evidence of GMO-specific risks, taking into consideration the EFSA 
GMO Panel Guidance for risk assessment of food and feed from genetically modified plants (EFSA, 
2011) as well as any related risk assessments carried out in the past. In addition, the GMO Panel 
considered the relevance of the concerns raised in the light of the most recent scientific data and 
relevant peer-reviewed publications regarding the use of specific antibiotic resistance genes as marker 
genes in GM plants. 
2. Concerns raised by Hungary 
The GMO Panel interprets the documentation provided by Hungary as raising the following issues: 
- antibiotic resistance genes can be transferred from the food into the intestinal flora, and there is a 
high risk of gene transfer from the GM potato into the bacteria living in the intestines of animals 
(Section 3.1); 
- gene transfer from cultivated GM potato plants in the soil bacteria escalates the multiplication of 
antibiotic resistance genes in the soil (Section 3.2); 
- there is a knowledge gap regarding up-to-date data on the prevalence of nptII in soil 
environments throughout Europe (Section 3.3); 
- there is a concern regarding the role of kanamycin and neomycin in relation to the treatment of 
tuberculosis and the possible appearance of resistance (Section 3.4). 
3. Risk assessment of the nptII gene 
3.1. Potential transfer of the nptII gene from GM potato into the intestinal flora 
Hungary provided several references to support its claims that numerous examples show that the 
antibiotic resistance genes can be transferred from the food into the intestinal flora, and that there is a 
high risk of gene transfer from the GM potato into the bacteria living in the intestines of animals 
(Chowdhury et al., 2003; Mazza et al., 2005; Alexander et al., 2007; Chainark et al., 2008; Tudisco et 
al., 2010). 
The review of Alexander et al. (2007) highlights an efficient degradation of DNA: no full-size 
transgenes were reported to be present in livestock. The review does not consider gene transfer from 
GM plants into the bacteria. Chainark et al. (2008) detected the presence of a recombinant CaMV 35S 
promoter fragment in the gastrointestinal tract content and blood (leucocytes) and tissue samples 
(kidney and muscle) of rainbow trout during feeding with GM soybean. Three to five days after 
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withdrawal of the GM feed, it was no longer detected. The study did not investigate the intestinal 
microbiota. The purpose of the study carried out by Chowdhury et al. (2003) was to determine if 
recombinant cry1Ab gene could be detected in the gastrointestinal contents of pigs fed GM maize. 
Fragments of the gene were detected in stomach, duodenal, ileal, caecal and rectal contents, but no 
evidence was provided for the transfer of the gene to the intestinal flora. The goal of the work of 
Mazza et al. (2005) was to assess the persistence of feed-derived cry1Ab fragments in the tissues 
(blood, spleen, liver, kidney, muscle) of piglets. Only a small fragment was detected, not the intact 
gene or its minimal functional unit. The intestinal microbiota was not analysed. Tudisco et al. (2010) 
analysed the presence of transgene fragments in blood and milk of goats fed GM soybean. The 
intestinal microbiota was not investigated. 
The GMO Panel assessed the literature cited in support of the Hungarian claims and concluded that no 
evidence was provided by Hungary to support the claim of a high risk of gene transfer from the GM 
potato into the intestinal flora of the animals. The GMO Panel has acknowledged this issue previously 
and assessed its implications (EFSA, 2009). There is no new information, either in the documentation 
submitted by Hungary or in the scientific literature, that would cause the Panel to change its former 
conclusions. Therefore, the GMO Panel reiterates its conclusion that, taking into account all the 
limitations of all current methodologies of detection, it can be expected that there is, at most, a low 
probability of transfer of antibiotic resistance genes from GM plants to bacteria in the digestive tract of 
humans and animals. If this transfer were to occur, it would take place at an extremely low frequency. 
In the risk assessment, the GMO Panel took into account the subsequent development and 
dissemination of resistance among bacteria. 
Furthermore, Hungary claims that, because of the “high-speed processing machines” used during 
potato harvesting, transgenic DNA might easily be exposed and the probability of horizontal gene 
transfer is much higher in animal (ruminant in particular) intestinal bacterial flora than in the case of 
intact cells and plant material (Chowdhury et al., 2003; Netherwood et al., 2004). The references 
provided do not support such claims.  
3.2. Potential transfer of the nptII gene from GM potato in the soil bacteria and between 
bacteria 
Hungary provides references meant to support its claim that there is a high risk of gene transfer from 
the GM potato in the soil bacteria (Martinez, 2009; Allen et al., 2010; Knapp et al., 2010), and that the 
production of GM plants escalates the multiplication of antibiotic resistance genes in the soil (Allen et 
al., 2010). 
The review of Allen et al. (2010) deals with antibiotic resistance genes in natural environments. Gene 
transfer from GM plants into the soil bacteria is not discussed, nor is there any indication that the 
production of GM plants escalates the multiplication of antibiotic resistance genes in the soil. Knapp et 
al. (2010) studied historical soil samples (from 1940 to 2008) from different locations in the 
Netherlands and concluded that antibiotic resistance genes from all classes of antibiotics tested (nptII 
or related genes were not studied) have significantly increased since 1940. It should be noted that this 
is not evidence for gene transfer from GM potato to soil bacteria. The review of Martinez (2009) 
discusses the possibilities of human pathogenic bacteria acquiring antibiotic resistance genes, e.g., 
from environmental microbes. Gene transfer from GM plants into soil bacteria is not discussed. In 
conclusion, no evidence was provided to support the claim of a high risk of gene transfer from the GM 
potato into the soil bacteria. 
Regarding the EFSA (2009) statement that antibiotic resistance occurs in nature in soil bacteria, 
Hungary provides literature to support the claims that the bacteria infecting animals and humans are 
not soil bacteria and that resistance is not frequent in these pathogens (Heinemann, 1999; Heinemann 
et al., 2000). Both reviews have a therapeutic focus, dealing with drug resistance in pathogens and the 
problem of antimicrobial drug design. They do not consider resistance frequencies or the 
differentiation between soil bacteria and human pathogenic bacteria. On the other hand, Hungary 
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provides literature to support the claim that the human and animal intestines facilitate the inter-
bacterial gene transfer and transfer from food-ingested bacteria into intestinal bacteria (Ferguson et al., 
2002; Hehemann et al., 2010). Ferguson et al. (2002) demonstrated gene transfer between Salmonella 
enterica serovar Typhimurium by conjugation inside cultured human epithelial cells. Hehemann et al. 
(2010) provided evidence that intestinal flora can acquire new genes from microbes living outside the 
gut, e.g., from seaweed-associated marine bacteria. Both examples deal with gene transfers between 
bacteria, and as such are not evidence for the transfer of genes from GM plants to microbes. 
Hungary concluded that there are no reliable data to document the likelihood of transfer of the nptII 
gene from GM plant to the bacterial flora. The GMO Panel acknowledged (EFSA, 2009) that there are 
uncertainties regarding the extent of horizontal gene transfer from plant DNA to bacteria in natural 
conditions (Nielsen et al., 2005), and regarding the impact that such transfers, compared with gene 
exchange, would have on bacterial populations. 
The GMO Panel further acknowledged (EFSA, 2009) the limitations in the screening of DNA uptake 
in natural bacterial communities (e.g., in soil or in the gut), including the limited ability to prove the 
uptake of DNA in the unculturable fraction, limited focus on anaerobic bacteria, a highly limited 
coverage of locations and time points, and the limited attention given to selection in driving the 
population dynamics of rare transformants (Heinemann and Traavik, 2004; Nielsen and Townsend, 
2004). 
The EFSA GMO Panel acknowledges that the distribution of nptII in naturally occurring bacteria may 
provide opportunities for transfer and recombination of this gene, or fragments thereof, among 
bacteria. Transfer of nptII among bacteria can occur by transformation, conjugation or transduction. 
Horizontal gene transfer from plant to bacteria can occur only by transformation and has only been 
shown to occur with plant DNA that has sequence similarity with the bacterial DNA. The EFSA GMO 
Panel therefore stresses that transfer of the nptII gene from plant to bacteria would be expected to 
occur with a frequency several orders of magnitude lower than the frequency obtained by transfer of 
DNA between bacteria (EFSA, 2009). 
There is no new information, either in the documentation submitted by Hungary or in the scientific 
literature, that would cause the Panel to change its previous conclusions. Therefore, the GMO Panel 
reiterates its conclusion that, taking into account all the limitations of all current methodologies of 
detection, it can be assumed that there is, at most, a low probability of transfer of antibiotic resistance 
genes from GM plants to bacteria in the environment. If this transfer were to occur, it would take place 
at an extremely low frequency. In the risk assessment, the GMO Panel took into account the 
consequential development and dissemination of resistance between bacteria if such transfer of 
antibiotic resistance would occur. 
3.3. Quantitative data on the occurrence of nptII in natural habitats 
The EFSA GMO Panel agrees with the Hungarian Authorities that there is a knowledge gap regarding 
up-to-date data on the prevalence of nptII in soil environments throughout Europe. The nptII gene 
occurs in bacteria at different frequencies in different species, isolates and environments (EFSA, 
2009). 
Recent metagenomic analyses of total bacterial populations (including non-culturable bacteria) have 
demonstrated that various types of resistance determinants, including resistance determinants for 
kanamycin and neomycin, have been detected in all the environments investigated (reviewed in EFSA, 
2009; Allen et al., 2010). These investigations indicate that aminoglycoside resistance determinants 
have a wide distribution, albeit at different frequencies, in different species, isolates and different 
environments, in naturally occurring bacteria. 
The EFSA GMO Panel points out that the use of antibiotics is a key factor in the selection and 
dissemination of antibiotic resistance genes in the immediate environment. While the key role of 
selection by antibiotic usage in the development of resistance is indisputable, some knowledge gaps 
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remain regarding the understanding of the natural reservoir of antibiotic resistance genes and their role 
in natural bacterial communities not exposed to industrially produced antibiotics, as previously 
concluded (EFSA, 2009). 
3.4. Multidrug-resistant tuberculosis and kanamycin 
The therapeutic relevance of kanamycin and neomycin was already addressed in the EFSA’s opinion 
on antibiotic resistance marker (ARM) genes (EFSA, 2009). Kanamycin is used as a second-line drug 
for the treatment of multiple drug-resistant tuberculosis (MTB). Multidrug-resistant (MDR) and 
extensively drug-resistant (XDR) tuberculosis (TB) (XDR-TB) are reported to have gradually spread 
across European countries with low TB prevalence (Cohen-Bacrie et al., 2011). By the end of 2010, 
68 countries, including 19 of the 27 countries in the EU, had reported at least one XDR-TB case 
(WHO, 2010). The increasing occurrence worldwide of TB isolates with resistance to second-line 
antibiotics such as kanamycin is a cause for global concern.  
It should be noted, however, that kanamycin resistance in the XDR-TB strains largely results from 
mutations in the 16S ribosomal RNA gene, the promoter of the enhanced intracellular survival gene 
(eis) and the glucose-inhibited division protein B gene (gidB). Thus, resistance to kanamycin in such 
strains is chromosomally encoded and has not developed as a result of the transfer of aminoglycoside 
resistance genes, such as nptII (Johnson et al., 2006; Zaunbrecher et al., 2009; Georghiou et al., 2012). 
CONCLUSIONS 
The EFSA GMO Panel examined the document submitted by Hungary. The Panel assessed whether 
the document contained new scientific information and concludes that: 
Hungary did not provide any new or additional information made available since the date of consent 
for this GM event that would affect the environmental risk assessment or the reassessment of existing 
information on the basis of new or additional scientific knowledge
4
. New data specific to the safety of 
the nptII gene have not been provided. 
The therapeutic relevance of kanamycin and neomycin was already addressed in the previous EFSA 
opinion on antibiotic resistance marker genes. Kanamycin resistance in Mycobacterium tuberculosis 
results largely from chromosomal mutations and not from the transfer of aminoglycoside resistance 
genes such as nptII. 
The knowledge gaps and uncertainties highlighted in the Hungarian document have already been 
considered in the previous EFSA opinion on antibiotic resistance marker genes. EFSA continually 
reviews the scientific literature. No new information on the safety of the nptII gene, as present in the 
GM potato EH92-527-1, was identified in the scientific literature that would cause the GMO Panel to 
change its earlier conclusions. 
The EFSA GMO Panel concludes that no detailed grounds exist to date that would lead to 
reconsideration of its opinion on GM potato EH92-527-1. 
DOCUMENTATION PROVIDED TO EFSA 
1. Letter, received 23 May 2012, with supporting document from Ladislav Miko, Deputy Director-
General for the food chain EC, to Catherine Geslain-Lanéelle, Executive Director EFSA (ref. 
SANCO/E1/MD/mp Ares(2012) 623655), requesting the assessment by EFSA of the scientific 
elements provided by Hungary in support of its decision to implement a national safeguard 
measure under Article 23 of Directive 2001/18/EC for GM potato EH92-527-1 and comprising the 
following supporting document: 
                                                     
4 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the 
environment of genetically modified organisms and repealing Council Directive 90/220/EEC. Official Journal of the 
European Communities L106: 1-38 (Article 23). 
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- Scientific and other proof relating to the Hungarian safety measure taken as regards the 
genetically modified Amflora potato. 
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